Fig. 2
From: Astragaloside IV inhibits astrocyte senescence: implication in Parkinson’s disease
AS-IV reduces senescence markers in astrocytes of the MPTP PD model. a–c RNA isolated from the substantia nigra compacta (SNc) tissues were analyzed for p16Ink4a (a) and SASP factor IL-1β (b) and IL-6 (c) mRNA levels by qPCR. Quantified data are normalized to the control group (the control group value is equal to 1). The data shown are the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. n = 5 for each group. d Representative immunofluorescence images showing p16Ink4a protein levels (red) in GFAP+ astrocytes (green) in the SNc. Scale bar 200/25 μm. e Representative immunofluorescence images showing lamin B1 protein levels (green) in GFAP+ astrocytes (red) in the SNc. Scale bar 25 μm. f Quantification of relative p16Ink4a fluorescence intensity in GFAP+ astrocytes (n = 4 for each group). g Quantification of relative lamin B1 fluorescence intensity in GFAP+ astrocytes (n = 3 for each group). Quantified data are normalized to the control group (the control group value is equal to 100%). The data shown are the mean ± SEM. *p < 0.05, **p < 0.01. AS-IV, Astragaloside IV; MPTP, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine